contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


cellink-ab-cellink-announces-collaboration-with-astrazeneca-to-utilize-cellinks-3d-bioprinting-technology-for-liver-organoid-culture

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

BICO Group operates in the biotechnology industry and focuses on the development and manufacturing of technologies for cell-based research and medical development. The company's products are aimed at researchers and pharmaceutical companies. The business is global with a main presence in Europe, North America and Asia. BICO Group was founded in 2016 and is headquartered in Gothenburg, Sweden.

BICO Group

CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced today that the company will collaborate with AstraZeneca to provide advanced...

CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced today that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.In tissue engineering, the need for assembly of three-dimensional (3D) tissues is important. 3D-bioprinting has emerged as a useful technology to recapitulate the microenvironment of native tissue, allowing for precise printing of multiple cells into a pre-defined position.CELLINK has an R&amp;D lab in AstraZeneca's BioVentureHub in Gothenburg, Sweden. The new collaboration will leverage CELLINK's innovative and patent-pending bioink, Extra Cellular Matrix and Laminin based bioinks, which enables human cells to grow and function as they would in the human body.For further information, please contact:Erik Gatenholm, CEOPhone (Sweden): +46 73 267 00 00Phone (US): +1 (650) 515 5566Email: <virtloc>eg@cellink.com</virtloc>Gusten Danielsson, CFOPhone (Sweden): +46 70 991 86 04Phone (US): +1 (857) 332 2138Email: <virtloc>gd@cellink.com</virtloc>About CELLINKCELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling &amp; bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.

Cellink AB: CELLINK announces collaboration with AstraZeneca to utilize CELLINKs' 3D-bioprinting technology for liver organoid culture